• Biospecifics Technologies Corp., of Lynbrook, N.Y., said its partner Auxilium Pharmaceuticals Inc., of Malvern, Pa., has entered a collaboration with Swedish Orphan Biovitrum AB (Sobi), of Stockholm, for the long-term development, supply and commercialization of Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture.